Summary

The global B-Cell Maturation Antigen (BCMA) Targeted Therapies market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry Forecast” looks at past sales and reviews total world B-Cell Maturation Antigen (BCMA) Targeted Therapies sales in 2024, providing a comprehensive analysis by region and market sector of projected B-Cell Maturation Antigen (BCMA) Targeted Therapies sales for 2025 through 2031. With B-Cell Maturation Antigen (BCMA) Targeted Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world B-Cell Maturation Antigen (BCMA) Targeted Therapies industry.
This Insight Report provides a comprehensive analysis of the global B-Cell Maturation Antigen (BCMA) Targeted Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on B-Cell Maturation Antigen (BCMA) Targeted Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global B-Cell Maturation Antigen (BCMA) Targeted Therapies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for B-Cell Maturation Antigen (BCMA) Targeted Therapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global B-Cell Maturation Antigen (BCMA) Targeted Therapies.
This report presents a comprehensive overview, market shares, and growth opportunities of B-Cell Maturation Antigen (BCMA) Targeted Therapies market by product type, application, key players and key regions and countries.
Segmentation by Type:
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells
Segmentation by Application:
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2020-2031)
2.1.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for B-Cell Maturation Antigen (BCMA) Targeted Therapies by Country/Region (2020, 2024 & 2031)
2.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Segment by Type
2.2.1 Bispecific Antibodies
2.2.2 Antibody Drug Conjugates
2.2.3 Chimeric Antigen Receptor T-Cells
2.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type
2.3.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Type (2020-2025)
2.4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Segment by Application
2.4.1 Liver Cancer
2.4.2 Respiratory Cancer
2.4.3 Brain Cancer
2.4.4 Others
2.5 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application
2.5.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Application (2020-2025)
3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Player
3.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Player
3.1.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Player (2020-2025)
3.1.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Player (2020-2025)
3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 B-Cell Maturation Antigen (BCMA) Targeted Therapies by Region
4.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2020-2025)
4.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Annual Revenue by Country/Region (2020-2025)
4.3 Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth (2020-2025)
4.4 APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth (2020-2025)
4.5 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth (2020-2025)
4.6 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth (2020-2025)
5 Americas
5.1 Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2020-2025)
5.2 Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2020-2025)
5.3 Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2020-2025)
6.2 APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2020-2025)
6.3 APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2020-2025)
7.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2020-2025)
7.3 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies by Region (2020-2025)
8.2 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2020-2025)
8.3 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
10.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Region (2026-2031)
10.1.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Region (2026-2031)
10.1.2 Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.1.3 APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.1.4 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.1.5 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.2 Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Country (2026-2031)
10.2.1 United States Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.2.2 Canada Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.2.3 Mexico Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.2.4 Brazil Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.3 APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Region (2026-2031)
10.3.1 China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
10.3.2 Japan Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.3.3 Korea Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.3.4 Southeast Asia Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.3.5 India Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.3.6 Australia Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.4 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Country (2026-2031)
10.4.1 Germany Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.4.2 France Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.4.3 UK Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.4.4 Italy Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.4.5 Russia Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.5 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Region (2026-2031)
10.5.1 Egypt Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.5.2 South Africa Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.5.3 Israel Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.5.4 Turkey Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
10.6 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Type (2026-2031)
10.7 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Application (2026-2031)
10.7.1 GCC Countries Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast
11 Key Players Analysis
11.1 Transposagen Biopharmaceuticals
11.1.1 Transposagen Biopharmaceuticals Company Information
11.1.2 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
11.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Transposagen Biopharmaceuticals Main Business Overview
11.1.5 Transposagen Biopharmaceuticals Latest Developments
11.2 Sutro Biopharma
11.2.1 Sutro Biopharma Company Information
11.2.2 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
11.2.3 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Sutro Biopharma Main Business Overview
11.2.5 Sutro Biopharma Latest Developments
11.3 Malin Corporation
11.3.1 Malin Corporation Company Information
11.3.2 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
11.3.3 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Malin Corporation Main Business Overview
11.3.5 Malin Corporation Latest Developments
11.4 Eureka Therapeutics
11.4.1 Eureka Therapeutics Company Information
11.4.2 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
11.4.3 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Eureka Therapeutics Main Business Overview
11.4.5 Eureka Therapeutics Latest Developments
11.5 firstVentury Equity
11.5.1 firstVentury Equity Company Information
11.5.2 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
11.5.3 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 firstVentury Equity Main Business Overview
11.5.5 firstVentury Equity Latest Developments
11.6 Five Prime Therapeutics
11.6.1 Five Prime Therapeutics Company Information
11.6.2 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
11.6.3 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Five Prime Therapeutics Main Business Overview
11.6.5 Five Prime Therapeutics Latest Developments
11.7 Credit Suisse Securities
11.7.1 Credit Suisse Securities Company Information
11.7.2 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
11.7.3 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Credit Suisse Securities Main Business Overview
11.7.5 Credit Suisse Securities Latest Developments
11.8 Dana-Farber Cancer Institute
11.8.1 Dana-Farber Cancer Institute Company Information
11.8.2 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
11.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Dana-Farber Cancer Institute Main Business Overview
11.8.5 Dana-Farber Cancer Institute Latest Developments
11.9 Deerfield Partners
11.9.1 Deerfield Partners Company Information
11.9.2 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
11.9.3 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Deerfield Partners Main Business Overview
11.9.5 Deerfield Partners Latest Developments
11.10 Onyx Pharmaceuticals
11.10.1 Onyx Pharmaceuticals Company Information
11.10.2 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
11.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Onyx Pharmaceuticals Main Business Overview
11.10.5 Onyx Pharmaceuticals Latest Developments
11.11 Juno Therapeutics
11.11.1 Juno Therapeutics Company Information
11.11.2 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
11.11.3 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Juno Therapeutics Main Business Overview
11.11.5 Juno Therapeutics Latest Developments
12 Research Findings and Conclusion